Department of Medicine I, University Medical Center Schleswig-Holstein-Campus Lübeck, 23558 Lübeck, Germany.
Department of Hemato-Oncology, University Medical Center Schleswig-Holstein-Campus Lübeck, 23558 Lübeck, Germany.
Int J Mol Sci. 2021 Oct 29;22(21):11780. doi: 10.3390/ijms222111780.
Liver metastases are the most common site of metastatic spread in colorectal cancer. Current treatment approaches involve effective systemic therapies in combination with surgical and/or interventional strategies. Multimodal strategies greatly improved clinical outcomes of patients with metastatic colorectal cancer over the last decades. Identification of predictive and prognostic biomarkers helped to comprehensively refine individual targeted treatment approaches and resulted in median overall survival rates of 30 months or longer. Current guidelines, thus, recommend treatment selection according to patients' performance status, tumor localization and stage as well as the tumor's molecular and genetic status. Here, we outline the latest developments in molecular decision-making for patients with upfront resectable, potentially or initially unresectable and non/never-resectable colorectal cancer liver metastases.
肝转移是结直肠癌最常见的转移部位。目前的治疗方法包括有效的全身治疗与手术和/或介入策略相结合。在过去几十年中，多模式策略极大地改善了转移性结直肠癌患者的临床结局。预测和预后生物标志物的鉴定有助于全面改进个体靶向治疗方法，并使中位总生存率达到 30 个月或更长。因此，目前的指南建议根据患者的体能状态、肿瘤定位和分期以及肿瘤的分子和遗传状态来选择治疗方法。在这里，我们概述了初治可切除、潜在或初始不可切除以及不可切除或从未切除的结直肠癌肝转移患者的分子决策的最新进展。
